About one in eight U.S. adults are currently taking a GLP-1 drug such as Ozempic, Wegovy, or Zepbound to treat diabetes, obesity, or other conditions, according to a KFF Health Tracking poll. But many suffer from significant side effects including nausea or vomiting. And for diabetic patients who also have conditions such as cancer or HIV, achieving glycemic control to effectively manage their blood sugar levels while avoiding weight or appetite loss is especially critical.

(MedPage Today) — An investigational GLP-1 receptor agonist pill edged out oral semaglutide (Rybelsus) for improving blood glucose in adults with type 2 diabetes inadequately controlled on metformin, the phase III ACHIEVE-3 trial showed.
Among…

An international clinical trial has found that an oral form of semaglutide, a widely used diabetes drug, reduced the risk of serious heart failure events in people with type 2 diabetes who already had heart failure. The findings, published in JAMA Internal Medicine, come from a large randomized trial of nearly 9,650 adults who have both type 2 diabetes and either cardiovascular disease or chronic kidney disease. Researchers followed participants for nearly four years as part of the Semaglutide Cardiovascular Outcomes, or SOUL, Trial. The results are from a secondary analysis of those data.

China’s National Medical Products Administration (NMPA) has accepted for review Jiuyuan Genetic Biopharmaceutical Co. Ltd.’s drug application for Jikeqin, a biosimilar product to Novo Nordisk A/S’s Wegovy (semaglutide) for obesity.

Orforglipron led to greater weight loss than semaglutide tablets and could offer more effective oral alternative to jabsA new daily pill could be a more effective GLP-1 tablet for weight loss, according to a clinical trial that may pave the way for an improved non-injection alternative to Wegovy and Mounjaro.The drug, called orforglipron and manufactured by Eli Lilly, is prescribed for type 2 diabetes and targets the same GLP-1 receptors as oral semaglutide. Like semaglutide, it lowers blood sugar levels, slows digestion and suppresses appetite. Unlike semaglutide tablets, it does not need to be taken on an empty stomach. Continue reading…

The second head-to-head Phase 3 trial in a week between dueling metabolic drugs from Eli Lilly and Novo Nordisk was reported Thursday. Once again, the data went Lilly’s way.

The latest data came from a …

A novel GLP-1 receptor agonist (RA) pill called orforglipron leads to a larger reduction in blood sugar levels after a year than the current available oral GLP-1 RA (semaglutide), finds a phase 3 randomized controlled trial published in The Lancet. Additionally, participants taking orforglipron had significantly greater reductions in body weight than those taking oral semaglutide.

INDIANAPOLIS, Feb. 26, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1…

Individuals living with type 2 diabetes (T2D) had a significantly lower risk of poor cardiovascular health when they used a GLP-1 receptor agonist (GLP-1 RA) in combination with adhering to healthy lifestyle habits, according to a new study led by researchers at Harvard T.H. Chan School of Public Health and the Department of Veterans Affairs Boston Healthcare System.

More than 200 participants enrolled as company targets topline data by end of 2026

WEDNESDAY, Feb. 25, 2026 — Some of the most popular diabetes and weight-loss drugs in the U.S. will soon cost a lot less.
Novo Nordisk announced Tuesday that it will cut U.S. list prices of Ozempic and Wegovy by up to 50% starting next…

Reports of people developing scurvy while taking GLP-1 medications are on the rise. Milles Team/Shutterstock

Reports of GLP-1 users developing scurvy have increased in recent months.

GLP-1 drugs can lead to malnutrition since they reduce appetite and food consumption.

(MedPage Today) — DENVER — People with HIV didn’t have a significant rise in depressive symptoms after starting semaglutide (Ozempic, Wegovy, Rybelsus) for diabetes or weight loss, according to a nine-site observational study.
After a median…

Novo Nordisk said that starting next year, it will lower the list price of its popular GLP-1 products to $675 per month in a cost-cutting effort focused on patients with high insurance deductibles or copays …

Plainsboro, NJ, US and Bagsværd, Denmark, February 24, 2026 –Today, Novo Nordisk announced that, effective January 1, 2027, the company will lower the list price, or wholesale acquisition cost (WAC), of Wegovy® (semaglutide)…

(MedPage Today) — Some participants in a weight-loss trial of retatrutide, an investigational triple-hormone receptor agonist, dropped out because they thought they were losing too much weight. (New York Times)
Meanwhile, UBT251, another investigational…

Following Monday’s clinical defeat by Eli Lilly, Novo Nordisk cut the 2027 list prices for its three GLP-1 medicines by as much as 50%, while boasting Phase 2 data for its invesigational triple-G agonist.

Starting in 2027, the Danish pharma firm will sell its weight-loss and diabetes drugs for $675 per month.

The Trump administration released detailed guidance for approving the first bespoke medicines crafted to treat individual patient mutations

Eli Lilly’s win in a head-to-head trial drove Novo Nordisk’s market cap to pre-Wegovy levels not long after the victor became the first pharma company to top a $1 trillion valuation. It seems one company can do no right, while the other can do no wrong.

Audience: Health Care Professional, Consumer January 13, 2026

FDA Evaluation Did Not Identify an Increased Risk of Suicidal Ideation or Behavior With the Use of GLP-1 RA Medications
This information is an update to the FDA Drug Safety…

(MedPage Today) — Meals and snacks with “GLP-1 Friendly” labels on the packaging are becoming more common in U.S. supermarkets as a growing number of Americans try obesity drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) to lose weight…

With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.

A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide, a Food and Drug Administration-approved drug for the treatment of overweight and obesity. The findings, published in The Lancet Obstetrics, Gynaecology, & Women’s Health, could expand treatment possibilities for millions of women struggling with obesity and obesity-related diseases after menopause.

Now that GLP-1 drugs have revolutionized how millions of Americans treat obesity and Type 2 diabetes, scientists are exploring the benefits of using the drugs for a host of other chronic diseases—many with few treatment options—such as heart failure, chronic liver disease, obstructive sleep apnea, and even substance use disorders.

Gordon Ramsay, celebrity chef, slams restaurants for creating Mounjaro-minded menus, calling the GLP-1-inspired dining trend “stupid” and “embarrassing.”

In this episode of Denatured, you’ll be listening to Jane Hughes, President of R&D and Co-founder of Verdiva Bio, and Jon Rees, CEO and Co-founder of MitoRx Therapeutics. We’ll discuss next-generation obesity solutions tackling GLP-1’s muscle loss and adherence challenges, through innovative muscle preservation, oral administration and combination therapy.

Some GLP-1 patients are begging to stay on the drugs just a little bit longer, presenting an ethical dilemma for doctors.

WEDNESDAY, Feb. 18, 2026 — The risk for nonscarring hair loss (NSHL) is increased in association with glucagon-like peptide-1 receptor agonist (GLP-1 RA) use, according to a study published online Feb. 9 in the Journal of the American Academy of…

(MedPage Today) — The meteoric rise of GLP-1 drugs for weight loss has raised concerns about potential malnutrition and even the comeback of scurvy. (The Hill)
An $80-per-month produce prescription subsidy failed to improve cardiometabolic health…

Soaring in popularity, GLP-1 medications—from weekly injections to newly available pills—are rapidly reshaping how Americans think about weight loss. In fact, a recent poll finds 1 in 8 adults are now taking medications like Ozempic or Wegovy for weight loss or chronic conditions, and use is expected to keep rising.

The FDA rejected a Disc Medicine therapy for a rare blood disorder, the first experimental drug to go through a new program to fast-track drug reviews

Novo Nordisk will slash U.S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% starting next year, the Danish drugmaker said on Tuesday

Medications for obesity may improve fertility, but there are many unknowns when it comes to using them during pregnancy.

FRIDAY, Feb. 20, 2026 — Satisfaction with semaglutide (Ozempic) is mainly driven by effective weight loss despite gastrointestinal side effects, according to a study published in the February issue of the Journal of Medical Internet…

FRIDAY, Feb. 20, 2026 — For patients with diabetes and overweight or obesity, tirzepatide use is associated with a lower incidence of new or progressive diabetic retinopathy (DR) and fewer complications, according to a study published online Jan…

Could weight-loss drugs shrink the body representation we’ve spent decades seeking?

For the first time, researchers show that tirzepatide—the active ingredient in the diabetes and weight-loss drug Mounjaro—reduces alcohol intake as well as relapse-like behaviors in rats and mice. The findings are considered relevant in the search for new treatments for alcohol use disorder. Researchers at the University of Gothenburg have previously demonstrated that semaglutide, found in the diabetes and weight-loss drugs Ozempic and Wegovy, reduces alcohol consumption in rats. In the current study, published in the journal eBioMedicine, the focus shifts to tirzepatide and Mounjaro.

Tirzepatide may help lower the risk of diabetic retinopathy, a diabetes complication that can lead to vision loss. Douglas Sacha/Getty Images

Weight loss medications Mounjaro and Zepbound, which contain the active ingredient tirzepatide, may lower the risk of diabetic retinopathy.

This diabetes complication occurs when high blood sugar levels damage the blood vessels in the retina at the back of the eye.

Hims & Hers said it pulled its controversial weight loss pill after discussions with “ecosystem stakeholders” during its fourth-quarter earnings call on Monday.

The comments come after Hims offered, then